Seek Returns logo

AMGN vs. ISRG: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at AMGN and ISRG, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolAMGNISRG
Company NameAmgen Inc.Intuitive Surgical, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyHealth Care Equipment & Supplies
Market Capitalization159.60 billion USD172.23 billion USD
ExchangeNasdaqGSNasdaqGS
Listing DateJune 17, 1983June 16, 2000
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of AMGN and ISRG by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

AMGN vs. ISRG: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolAMGNISRG
5-Day Price Return2.12%0.71%
13-Week Price Return7.47%-14.45%
26-Week Price Return-0.18%-18.76%
52-Week Price Return-9.61%-0.35%
Month-to-Date Return0.46%-0.13%
Year-to-Date Return13.74%-7.95%
10-Day Avg. Volume1.97M1.62M
3-Month Avg. Volume2.55M1.82M
3-Month Volatility26.01%21.21%
Beta0.491.64

Profitability

Return on Equity (TTM)

AMGN

97.92%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

AMGN’s Return on Equity of 97.92% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

ISRG

15.55%

Health Care Equipment & Supplies Industry

Max
34.53%
Q3
19.38%
Median
9.52%
Q1
4.86%
Min
-7.58%

ISRG’s Return on Equity of 15.55% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.

AMGN vs. ISRG: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

AMGN

18.96%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

A Net Profit Margin of 18.96% places AMGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

ISRG

28.51%

Health Care Equipment & Supplies Industry

Max
23.34%
Q3
13.06%
Median
9.53%
Q1
5.96%
Min
-3.87%

ISRG’s Net Profit Margin of 28.51% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

AMGN vs. ISRG: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

AMGN

24.01%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

An Operating Profit Margin of 24.01% places AMGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

ISRG

28.80%

Health Care Equipment & Supplies Industry

Max
29.44%
Q3
17.80%
Median
13.95%
Q1
8.73%
Min
-3.56%

An Operating Profit Margin of 28.80% places ISRG in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

AMGN vs. ISRG: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

SymbolAMGNISRG
Return on Equity (TTM)97.92%15.55%
Return on Assets (TTM)7.35%13.75%
Net Profit Margin (TTM)18.96%28.51%
Operating Profit Margin (TTM)24.01%28.80%
Gross Profit Margin (TTM)69.71%66.61%

Financial Strength

Current Ratio (MRQ)

AMGN

1.31

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

AMGN’s Current Ratio of 1.31 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ISRG

5.64

Health Care Equipment & Supplies Industry

Max
4.90
Q3
3.05
Median
2.14
Q1
1.49
Min
0.86

ISRG’s Current Ratio of 5.64 is exceptionally high, placing it well outside the typical range for the Health Care Equipment & Supplies industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

AMGN vs. ISRG: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

AMGN

7.57

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

With a Debt-to-Equity Ratio of 7.57, AMGN operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

ISRG

0.00

Health Care Equipment & Supplies Industry

Max
1.49
Q3
0.71
Median
0.45
Q1
0.14
Min
0.00

Falling into the lower quartile for the Health Care Equipment & Supplies industry, ISRG’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

AMGN vs. ISRG: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

AMGN

2.40

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

AMGN’s Interest Coverage Ratio of 2.40 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

ISRG

--

Health Care Equipment & Supplies Industry

Max
58.29
Q3
25.56
Median
9.06
Q1
3.60
Min
-28.92

Interest Coverage Ratio data for ISRG is currently unavailable.

AMGN vs. ISRG: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

SymbolAMGNISRG
Current Ratio (MRQ)1.315.64
Quick Ratio (MRQ)0.984.89
Debt-to-Equity Ratio (MRQ)7.570.00
Interest Coverage Ratio (TTM)2.40--

Growth

Revenue Growth

AMGN vs. ISRG: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

AMGN vs. ISRG: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

AMGN

3.06%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

AMGN’s Dividend Yield of 3.06% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

ISRG

0.00%

Health Care Equipment & Supplies Industry

Max
4.05%
Q3
1.76%
Median
0.71%
Q1
0.00%
Min
0.00%

ISRG currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

AMGN vs. ISRG: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

AMGN

82.64%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

At 82.64%, AMGN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

ISRG

0.00%

Health Care Equipment & Supplies Industry

Max
160.00%
Q3
72.47%
Median
27.49%
Q1
0.00%
Min
0.00%

ISRG has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

AMGN vs. ISRG: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

SymbolAMGNISRG
Dividend Yield (TTM)3.06%0.00%
Dividend Payout Ratio (TTM)82.64%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

AMGN

24.22

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

AMGN’s P/E Ratio of 24.22 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

ISRG

66.01

Health Care Equipment & Supplies Industry

Max
73.48
Q3
51.69
Median
34.31
Q1
25.74
Min
11.47

A P/E Ratio of 66.01 places ISRG in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

AMGN vs. ISRG: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

AMGN

4.59

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

AMGN’s P/S Ratio of 4.59 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ISRG

18.82

Health Care Equipment & Supplies Industry

Max
9.53
Q3
5.26
Median
3.39
Q1
2.13
Min
0.00

With a P/S Ratio of 18.82, ISRG trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

AMGN vs. ISRG: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

AMGN

20.21

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

AMGN’s P/B Ratio of 20.21 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

ISRG

10.85

Health Care Equipment & Supplies Industry

Max
10.85
Q3
5.98
Median
3.48
Q1
2.43
Min
0.69

ISRG’s P/B Ratio of 10.85 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

AMGN vs. ISRG: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

SymbolAMGNISRG
Price-to-Earnings Ratio (TTM)24.2266.01
Price-to-Sales Ratio (TTM)4.5918.82
Price-to-Book Ratio (MRQ)20.2110.85
Price-to-Free Cash Flow Ratio (TTM)14.6186.31